CytomX Therapeutics (STU:6C1) EBIT per Share : €0.28 (TTM As of Dec. 2024)

View and export this data going back to 2016. Start your Free Trial

What is CytomX Therapeutics EBIT per Share?

CytomX Therapeutics's EBIT per Share for the three months ended in Dec. 2024 was €0.20. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024 was €0.28.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for CytomX Therapeutics's EBIT per Share or its related term are showing as below:

During the past 12 years, the highest 3-Year average EBIT per Share Growth Rate of CytomX Therapeutics was 63.10% per year. The lowest was -56.60% per year. And the median was -5.40% per year.

STU:6C1's 3-Year EBIT Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 8
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

CytomX Therapeutics's EBIT for the three months ended in Dec. 2024 was €16.9 Mil.

CytomX Therapeutics EBIT per Share Historical Data

The historical data trend for CytomX Therapeutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CytomX Therapeutics EBIT per Share Chart

CytomX Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EBIT per Share

Get a 7-Day Free Trial

-1.44

-1.60

-1.46

-0.08

0.28

CytomX Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
EBIT per Share	Get a 7-Day Free Trial															-0.01	0.13	-0.09	0.04	0.20

CytomX Therapeutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

CytomX Therapeutics's EBIT per Share for the fiscal year that ended in Dec. 2024 is calculated as

	EBIT per Share		(A: Dec. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	23.87	/	84.745
=	0.28

CytomX Therapeutics's EBIT per Share for the quarter that ended in Dec. 2024 is calculated as

	EBIT per Share		(Q: Dec. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	16.883	/	85.742
=	0.20

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.28

CytomX Therapeutics (STU:6C1) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

CytomX Therapeutics EBIT per Share Related Terms

Thank you for viewing the detailed overview of CytomX Therapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

CytomX Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CytomX Therapeutics Inc (STU:6C1) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

CTMX:USA 6C1:Germany

Address

151 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080

Website

https://www.cytomx.com

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

CytomX Therapeutics Headlines

No Headlines